Navigation Links
Keystone Symposia launches 2013-14 meeting series with first conference in Rio de Janeiro
Date:11/1/2013

Keystone Symposia is today convening the first conference of its 2013-2014 meeting season and its first in Rio de Janeiro, Brazil on "Advancing Vaccines in the Genomics Era" at the Windsor Barra Hotel immediately following the conclusion of the Grand Challenges in Global Health meeting for that program's grantees. The four-day conference is part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation, which has funded travel awards for 27 investigators from developing countries to attend. It is also sponsored by FAPERJ the Rio de Janeiro State Agency for Research Development.

Scientific organizers of the meeting are Bali Pulendran of Emory University, Chris Wilson of Bill & Melinda Gates Foundation and Rino Rappuoli of Novartis Vaccines & Diagnostics.The focus is on the design and development of vaccines leveraging advances in systems and structural biology.

One of the key presentations at the meeting will be by Peter Kwong of the National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health on Sunday morning, November 3. His paper, published in Science on November 1, demonstrates the efficacy of a new fusion glycoprotein vaccine for RSV (Respiratory Syncytial Virus), which was developed at NIAID using structure-based design. RSV is the leading cause of hospitalization for children under five years of age, plus responsible for 6.75% of deaths in children one month to one year of age and in the elderly at levels comparable to influenza virus. The vaccine is the first time the "Antibody-to-Vaccine" paradigm driving the HIV and universal flu efforts has been shown to work. More details are available in NIAID's press release at http://www.niaid.nih.gov/news/newsreleases/2013/Pages/RSV-vax.aspx.

"The publication of the work on RSV as our meeting convenes in Rio is an additional demonstration of how new, revolutionary technologies are making it possible to develop novel vaccines, and how timely and important is this Keystone Symposia meeting," commented Rino Rappuoli.


'/>"/>

Contact: Yvonne Psaila
yvonnep@keystonesymposia.org
970-262-2676
Keystone Symposia on Molecular & Cellular Biology
Source:Eurekalert

Related biology news :

1. Keystone Symposia announces grant from Alfred P. Sloan Foundation
2. Natural keystone molecules punch over their weight in ecosystems
3. Entomology 2012 to present 105 insect symposia in November
4. BiOptix to highlight new 404pi instrument at European symposia
5. LABS, Inc. Launches Suite of Next-Generation Test Offerings; Focuses on Expanding Complex Biologic Testing Portfolio in 2012
6. Elsevier launches new journal Algal Research
7. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
8. Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes
9. WanderID Launches Breakthrough ID Product for Children, Seniors
10. Wiley-Blackwell launches new open-access journal: Food Science & Nutrition
11. MindSpec launches online Autism Reading Room
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
Breaking Biology News(10 mins):
(Date:3/1/2017)... and NEW YORK , ... Group (SELLAS or the Company), a late-stage biopharmaceutical ... list of cancer indications, today reported updated positive ... treatment, galinpepimut-S, in multiple myeloma (MM) patients. Consistent ... meaningful clinical benefit among high-risk MM patients, positioning ...
(Date:3/1/2017)... 2017 Illustris Pharmaceuticals, Inc. today announced the ... delivery technology platform.  The leadership team consists of ... Prygocki , former President of Medicis, Dr. Jacob ... , founding member of Derma-Rx and IDS Clinic and ... in Asia , and Andrew ...
(Date:3/1/2017)... Fla. , March 1, 2017  Friends, family, ... living with multiple sclerosis (MS), a chronic condition affecting ... MSWorld , MS Views and News , ... the Multiple Sclerosis Foundation — have joined biotechnology ... partners through the #MySupportHero initiative. During MS Awareness Month, ...
(Date:3/1/2017)... ... March 01, 2017 , ... At interpack ... concentrating on protection, productivity and quality can help food and pharmaceutical manufacturers improve ... – from x-ray and checkweighing to vision inspection and metal detection – will ...
Breaking Biology Technology: